The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of Salivary Cortisol Hypertension Assay

18 Dec 2015 09:43

RNS Number : 5543J
Immunodiagnostic Systems Hldgs PLC
18 December 2015
 

Launch of IDS-iSYS Salivary Cortisol Hypertension Assay

18 December 2015

 

Immunodiagnostic Systems Holdings plc.

Launch of IDS-iSYS Salivary Cortisol Hypertension Assay

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, has launched the IDS-iSYS Salivary Cortisol assay in the European market - a fully automated assay for use with the IDS-iSYS Automated System.

The launch of the IDS-iSYS Salivary Cortisol assay enhances the IDS Hypertension panel, which also includes the automated IDS-iSYS Aldosterone and IDS-iSYS Direct Renin immunoassays.

The IDS-iSYS Salivary Cortisol assay measures a patient's salivary cortisol and offers clinicians an easy, non-invasive way to diagnose diseases of cortisol imbalance such as Cushing's Syndrome (CS). One sign of CS is a higher than expected level of cortisol, which can often lead to hypertension.

As the fastest salivary cortisol automated test on the market the IDS-iSYS Salivary Cortisol assay allows laboratories to benefit from a reduced time to first result.

The global market size of salivary cortisol testing is estimated to be around £5 - £10 million.

For further information:

Immunodiagnostic Systems Holdings plc Telephone: +44(0)191 519 0660Patricio Lacalle, CEOJaap Stuut, Marketing DirectorPeel Hunt LLP Telephone: +44(0)207 418 8900James Steel

 

About Immunodiagnostic Systems Holdings plc.:A Specialist in Endocrinology TestingImmunodiagnostic Systems Holdings plc (IDS) is a leading in vitro diagnostic solution provider to the clinical laboratory market. IDS develop, manufacture and market innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients. The IDS immunoassay portfolio is a combination of an endocrinology specialty testing menu and assay panels in complementary fields.

IDS was founded in 1977 and trades on the Alternative Investment Market (AIM; trading symbol IDH) of the London Stock Exchange.IDS is a global company headquartered in the UK with around 400 employees worldwide. The group's products are developed and manufactured at their facilities in Europe. IDS serve customers through regional offices in Europe, U.S.A. and Brazil. The group's network of distributors work on IDS' behalf to serve customers throughout the rest of the world.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGCBDDDSBBGUI
Date   Source Headline
17th May 20217:00 amRNSOffer for Immunodiagnostic Systems Holdings Plc
16th Apr 20217:00 amRNSFY21 Trading Update
29th Mar 20217:00 amRNSFDA EUA for automated IgG SARS-CoV-2 assay
27th Nov 20209:05 amRNSSecond Price Monitoring Extn
27th Nov 20209:00 amRNSPrice Monitoring Extension
27th Nov 20207:00 amRNSLaunch of SARS-CoV-2 Antigen Rapid Tests
20th Nov 20206:22 pmRNSInterim Results - period ended 30 September 2020
26th Oct 20209:05 amRNSSecond Price Monitoring Extn
26th Oct 20209:00 amRNSPrice Monitoring Extension
23rd Oct 20204:35 pmRNSH1 Trading Update
9th Oct 20207:00 amRNSAssay to detect IgM SARS-CoV-2 antibodies launch
16th Sep 20207:00 amRNSNew TDM assays launched for use on the IDS-iSYS
14th Sep 20202:39 pmRNSDirector/PDMR Shareholding
27th Aug 20207:00 amRNSSARS-CoV-2 manufacturing agreement
13th Aug 20204:40 pmRNSSecond Price Monitoring Extn
13th Aug 20204:35 pmRNSPrice Monitoring Extension
13th Aug 20207:00 amRNSAutomated IgM assay to detect SARS-CoV-2
4th Aug 20204:18 pmRNSLaunch of automated IDS Cortisol assay
23rd Jul 20202:57 pmRNSResults of AGM
23rd Jul 20207:00 amRNSAGM Statement
17th Jul 202010:40 amRNSDirector/PDMR Shareholding
16th Jul 20201:45 pmRNSDirector/PDMR Shareholding
30th Jun 20209:05 amRNSSecond Price Monitoring Extn
30th Jun 20209:00 amRNSPrice Monitoring Extension
30th Jun 20207:00 amRNSLaunch of assay to detect SARS-CoV-2 antibodies
17th Jun 20208:35 amRNSPublication of Annual Report and Accounts
17th Jun 20207:00 amRNSFinal Results
12th Jun 20209:06 amRNSSecond Price Monitoring Extn
12th Jun 20209:00 amRNSPrice Monitoring Extension
12th Jun 20207:00 amRNSAutomated assay to detect SARS-CoV-2 antibodies
17th Apr 20204:35 pmRNSFY20 Trading Update
31st Mar 202011:00 amRNSDirector/PDMR Shareholding
21st Feb 20204:11 pmRNSDirector/PDMR Shareholding
21st Feb 20209:11 amRNSDirector/PDMR Shareholding
20th Feb 20204:49 pmRNSDirector/PDMR Shareholding
22nd Nov 20194:35 pmRNSHalf-year Report
18th Oct 20194:35 pmRNSTrading Statement
25th Jul 20193:34 pmRNSResult of AGM
25th Jul 20197:00 amRNSAGM Statement
11th Jul 20192:16 pmRNSDirector/PDMR Shareholding
5th Jul 201910:02 amRNSDirector/PDMR Shareholding
19th Jun 20197:05 amRNSPublication of Annual Report and Accounts
19th Jun 20197:00 amRNSFinal Results
22nd May 20192:05 pmRNSSecond Price Monitoring Extn
22nd May 20192:00 pmRNSPrice Monitoring Extension
18th Apr 20194:35 pmRNSFY2019 Trading Update
12th Mar 201911:55 amRNSChange of Auditor
7th Jan 20198:20 amRNSDirector/PDMR Shareholding
18th Dec 20181:42 pmRNSDirector/PDMR Shareholding
6th Dec 20185:13 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.